Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd.    4523   JP3160400002

EISAI CO., LTD.

(4523)
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2020 682 B
EBIT 2020 108 B
Net income 2020 78 194 M
Finance 2020 164 B
Yield 2020 2,80%
Sales 2021 679 B
EBIT 2021 103 B
Net income 2021 72 457 M
Finance 2021 209 B
Yield 2021 2,82%
P/E ratio 2020 20,5x
P/E ratio 2021 21,1x
EV / Sales2020 2,09x
EV / Sales2021 2,03x
Capitalization 1 590 B
More Financials
Company
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (92.2%): prescribed drugs, health products, etc.; - other (7.8%): food additives, chemical products, etc. Net sales are... 
Sector
Pharmaceuticals
Calendar
10/30Earnings Release
More about the company
Surperformance© ratings of Eisai Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on EISAI CO., LTD.
10/16EISAI : New drug approval for fycompa for adjunctive treatment of partial onset ..
AQ
10/15EISAI : New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset ..
AQ
10/02MERCK AND : Eisai - Final Study Results Evaluating LENVIMA plus KEYTRUDA Combina..
AQ
09/30EISAI : Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembr..
AQ
09/29EISAI : and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceuti..
AQ
09/27EISAI : And fronteo to launch coroban - tumbling and falling prediction system f..
AQ
09/27EISAI CO., LTD : Ex-dividend day for interim dividend
FA
09/26EISAI : and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence a..
AQ
09/26EISAI : and Fronteo to Launch Coroban Tumbling and Falling Prediction System for..
AQ
09/23EISAI : to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Cong..
AQ
09/23EISAI : And meiji announce parkinson's disease treatment equfina tablets approve..
AQ
09/23EISAI : Promotion and distribution agreement with mylan india for eribulin secon..
AQ
09/23Newron Pharmaceuticals - Commercialization partner Meiji Seika together with ..
AQ
09/20EISAI : to Present New 12-month Safety & Effectiveness Data from Phase 3 Lembore..
AQ
09/20EISAI : and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safina..
AQ
More news
News in other languages on EISAI CO., LTD.
09/27EISAI CO., LTD : Ex-dividend day for interim dividend
09/20NEWRON : Safinamide (Parkinson) homologué au Japon
09/20Newron-Partner erhalten Zulassung für Safinamide bei Parkinson in Japan
07/22Tokyo finit en repli, spéculations autour de la Fed
06/21Tokyo finit en nette baisse, plombée par le yen
More news
Analyst Recommendations on EISAI CO., LTD.
More recommendations
Sector news : Pharmaceuticals - NEC
10/18More Money Demanded in Opioid Settlement Talks -- Update
DJ
10/18More Money Demanded in Opioid Settlement Talks
DJ
10/18JOHNSON & JOHNSON : J&J Recalls Baby Powder on Asbestos Concern -- 2nd Update
DJ
10/18Sanofi pulls Zantac from U.S. and Canada after carcinogen found
RE
10/18Johnson & Johnson Down Over 5%, on Pace for Largest Percent Decrease Since De..
DJ
More sector news : Pharmaceuticals - NEC
Technical analysis trends EISAI CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 5 886,15  JPY
Last Close Price 5 550,00  JPY
Spread / Highest target 53,2%
Spread / Average Target 6,06%
Spread / Lowest Target -38,7%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Director
Yutaka Tsuchiya Director
Hirokazu Kanai Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD.-33.08%14 652
JOHNSON & JOHNSON4.74%359 375
ROCHE HOLDING AG18.49%249 453
MERCK AND COMPANY9.67%214 559
PFIZER-16.47%201 662
NOVARTIS15.95%199 827